Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MODIFI-IBD: Modafinil for debilitating fatigue in quiescent inflammatory bowel disease
2026-525163-41-00Phase 3Authorised
- Sponsor
- Radboud University Medical Center
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthenia and inflammatory bowel disease (IBD) comparing Modafinil (Modiodal) with Placebo (2 arms). Primary endpoint: Change in IBD-F section I score at week 8. Planned start May 2026; status: authorised.
02
Drugs
modafinil
03
Conditions
astheniainflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2026-525163-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525163-41-00.